About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01477489

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Study identifier: NCT01477489
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Breast cancer with either

a) locoregional recurrence after previous mastectomy or,
b) inflammatory breast cancer status post mastectomy for which radiotherapy to the chest wall and regional nodes is planned as part of treatment.
Patients with Stage IV disease are eligible as long as they meet these criteria.

Type of study:

Phase I study

Treatment:

Veliparib twice daily and standard radiation treatment

Study sites:

Massachusetts
Boston
Dana-Farber Cancer Institute
Contact: Nicole Ryabin 617-632-6767 nryabin@partners.org
Contact: Jennifer Bellon 617-632-3591 jbellon@partners.org

Michigan
Ann Arbor
University of Michigan
Contact: Cancer Answer Line 800-865-1125 canceranswerline@umich.edu
Contact: Michelle Castle 734-615-8492 michcast@med.umich.edu

New York
New York City
Memorial Sloan Ketter Cancer Center

Contact: Dr. Beryl McCormick: 212-639-6756 mccormib@mskcc.org

Page updated 07/08/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org